Last-Resort combo for advanced melanoma now available through expanded access
NCT ID NCT06590480
First seen Jan 05, 2026 · Last updated May 07, 2026 · Updated 21 times
Summary
This program provides early access to a combination of VO (vusolimogene oderparepvec) and nivolumab for adults with advanced melanoma that has worsened after anti-PD-1 treatment. The goal is to offer a potential treatment option while collecting real-world data. Participants must have unresectable or metastatic melanoma and meet other eligibility criteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.